Edgewise a new buy at Guggenheim on two pipeline prospects
Source: SeekingAlpha
2025-04-30 13:44:46 ET
More on Edgewise Therapeutics
- Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
- Edgewise Therapeutics: More Expensive Now, But Much More Derisked
- Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes
- Edgewise Therapeutics downgraded at Scotiabank on heart disease trial results
- Seeking Alpha’s Quant Rating on Edgewise Therapeutics
Read the full article on Seeking Alpha
For further details see:
Edgewise a new buy at Guggenheim on two pipeline prospects
Edgewise Therapeutics Inc.
NASDAQ: EWTX
EWTX Trading
-2.68% G/L:
$38.01 Last:
991,914 Volume:
$40 Open:
EWTX Latest News
EWTX Stock Data
$3,280,862,770
54,628,112
N/A
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Boulder
